Pulmonx annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
Pulmonx R&D Spending Growth & History (LUNG)
Pulmonx's r&d spending was $19.5M for fiscal 2025.
View full Pulmonx company overviewPulmonx annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.5M | $1.9M | +10.93% |
| 2024 | 2024-12-31 | $17.6M | −$510,000 | −2.82% |
| 2023 | 2023-12-31 | $18.1M | $2.7M | +17.43% |
| 2022 | 2022-12-31 | $15.4M | $2.3M | +17.87% |
| 2021 | 2021-12-31 | $13.1M | $5.6M | +75.11% |
| 2020 | 2020-12-31 | $7.5M | $1.4M | +23.33% |
| 2019 | 2019-12-31 | $6.0M | −$942,000 | −13.47% |
| 2018 | 2018-12-31 | $7.0M | — | — |
Pulmonx quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.0M | −$272,000 | −5.13% |
| Q1 2026 | 2026-03-31 | $4.9M | $143,000 | +3.01% |
| Q4 2025 | 2025-12-31 | $4.6M | $582,000 | +14.55% |
| Q3 2025 | 2025-09-30 | $4.8M | $1.1M | +29.43% |
| Q2 2025 | 2025-06-30 | $5.3M | −$309,000 | −5.50% |
| Q1 2025 | 2025-03-31 | $4.8M | $546,000 | +12.97% |
| Q4 2024 | 2024-12-31 | $4.0M | $104,000 | +2.67% |
| Q3 2024 | 2024-09-30 | $3.7M | −$476,000 | −11.28% |
| Q2 2024 | 2024-06-30 | $5.6M | −$95,000 | −1.66% |
| Q1 2024 | 2024-03-31 | $4.2M | −$43,000 | −1.01% |
| Q4 2023 | 2023-12-31 | $3.9M | −$6,000 | −0.15% |
| Q3 2023 | 2023-09-30 | $4.2M | −$146,000 | −3.34% |
| Q2 2023 | 2023-06-30 | $5.7M | $2.1M | +58.88% |
| Q1 2023 | 2023-03-31 | $4.3M | $719,000 | +20.35% |
| Q4 2022 | 2022-12-31 | $3.9M | $195,000 | +5.26% |
| Q3 2022 | 2022-09-30 | $4.4M | $1.6M | +55.10% |
| Q2 2022 | 2022-06-30 | $3.6M | $88,000 | +2.51% |
| Q1 2022 | 2022-03-31 | $3.5M | $500,000 | +16.48% |
| Q4 2021 | 2021-12-31 | $3.7M | $1.2M | +50.00% |
| Q3 2021 | 2021-09-30 | $2.8M | $818,000 | +40.96% |
| Q2 2021 | 2021-06-30 | $3.5M | $2.1M | +145.86% |
| Q1 2021 | 2021-03-31 | $3.0M | $1.5M | +93.87% |
| Q4 2020 | 2020-12-31 | $2.5M | — | — |
| Q3 2020 | 2020-09-30 | $2.0M | $598,000 | +42.74% |
| Q2 2020 | 2020-06-30 | $1.4M | — | — |
| Q1 2020 | 2020-03-31 | $1.6M | — | — |
| Q3 2019 | 2019-09-30 | $1.4M | — | — |
Pulmonx r&d spending trends
Over the last five fiscal years, Pulmonx's r&d spending increased from $7.5M to $19.5M, a change of $12.0M. The latest reported quarter, Q2 2026, shows $5.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pulmonx source filings ↗